Edwards Lifesciences Corp (EW)

Net profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	4,174,600	4,158,900	1,473,000	1,413,800	1,402,400	1,430,900	1,389,500	1,488,800	1,521,900	1,458,800	1,455,400	1,538,500	1,503,100	1,477,300	1,462,400	851,000	823,400	794,100	743,600	1,107,800
Revenue (ttm)	US$ in thousands	5,724,300	5,872,600	5,999,100	6,143,400	6,004,800	5,819,000	5,657,100	5,500,800	5,382,400	5,363,800	5,355,000	5,357,100	5,232,500	5,094,500	4,925,200	4,474,200	4,386,300	4,368,700	4,321,800	4,483,700
Net profit margin		72.93%	70.82%	24.55%	23.01%	23.35%	24.59%	24.56%	27.07%	28.28%	27.20%	27.18%	28.72%	28.73%	29.00%	29.69%	19.02%	18.77%	18.18%	17.21%	24.71%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $4,174,600K ÷ $5,724,300K
= 72.93%

The net profit margin of Edwards Lifesciences Corp has shown fluctuations over the past few years, with a general increasing trend followed by a significant spike in the most recent periods. The net profit margin stood at around 24-29% from March 2020 to June 2021, indicating healthy profitability levels. There was a sudden increase to over 70% in the net profit margin in the last two quarters of 2024, which could be attributed to exceptional performance or one-time gains impacting the bottom line significantly.

It is essential to delve deeper into the financial statements and disclosures to understand the factors driving this sharp increase in net profit margin in the last two quarters of 2024. Moreover, it would be prudent to analyze the sustainability and the underlying reasons for such a spike in profitability to assess the company's long-term financial health and performance.